Shares of the Massachusetts-based pharmaceutical company were recently down 6% to $178.50 in morning trading. The stock is about 35% below its 52-week peak of $275. The company said there is a ...
“Risk appetite has fallen in January as investors take stock of a revised outlook for rates and pare back their optimism on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback